BRIEF-Ziopharm says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma

* Ziopharm Oncology says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma - Sec Filing
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.